Elisabetta Magistretti Acquires Shares in Stevanato Group S.p.A.
Elisabetta Magistretti purchased 4,975 shares of Stevanato Group S.p.A. on June 12.
Key Points
- Elisabetta Magistretti bought 4,975 shares of Stevanato Group S.p.A. (NYSE:STVN) on June 12, 2026.
- Shares traded near $18.39 on Friday, with a market cap of $5.02 billion and a P/E ratio of 31.71.
- Recent analyst ratings include TD Cowen initiating a buy rating with a $25 price target on June 16, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Elisabetta Magistretti purchased 4,975 shares of Stevanato Group S.p.A. (NYSE:STVN) on June 12, 2026. This transaction, not part of a pre-planned trading program, adds to her holdings in the company. Shares of Stevanato Group traded near $18.39 on Friday.
Other Institutional Activity in Stevanato Group
Several institutional investors have adjusted their positions in Stevanato Group. Conestoga Capital Advisors, LLC grew its holdings by 602,050 shares, ending with 8,491,751 shares valued at about $116.8 million, a 7.6% increase. Meanwhile, Neuberger Berman Group LLC reduced its position by 312,219 shares, bringing its total to 4,475,492 shares worth approximately $61.5 million, a 6.5% decrease. T. Rowe Price Investment Management, Inc. cut its stake by 698,724 shares, holding 3,224,908 shares valued at around $44.3 million, marking a 17.8% decrease. Conversely, Bamco Inc /NY/ increased its holdings by 498,714 shares, totaling 2,500,438 shares valued at about $34.4 million, a 24.9% rise.
Stevanato Group S.p.A. Stock Down 12.6%
Shares of Stevanato Group S.p.A. (NYSE:STVN) traded near $18.39 on Friday. The company has a market capitalization of $5.02 billion and a P/E ratio of 31.71. It operates with a beta of 0.776, indicating lower volatility compared to the market. The stock has experienced a 52-week low of $12.89 and a high of $28.00, with a 50-day moving average of $17.39 and a 200-day moving average of $19.57. Stevanato Group maintains a current ratio of 1.63 and a quick ratio of 1.11, with a debt-to-equity ratio of 29.43.
$STVN stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
In its most recent earnings report, Stevanato Group S.p.A. posted revenue of $1.20 billion, reflecting a growth rate of 6.6%. The company reported an EPS of $0.58, with a net margin of 11.7% and a return on equity of 9.6%. The next earnings date is anticipated on May 7, 2026.
Dividend
Stevanato Group S.p.A. offers an annual dividend rate of $0.06, providing a yield of 0.34%. The company's dividend payout ratio stands at 10.6%.
Insider Buying and Selling at Stevanato Group S.p.A.
On June 12, 2026, Elisabetta Magistretti purchased 4,975 shares of Stevanato Group S.p.A. Additionally, Marco Dal Lago, the Chief Financial Officer, bought 2,356 shares on the same day. These transactions were not conducted under Rule 10b5-1 plans. Meanwhile, on June 15, 2026, several insiders, including Karen Flynn and William Federici, each sold 1,493 shares at an average price of $17.09.
Analysts Set New Price Targets
On June 16, 2026, TD Cowen initiated coverage on Stevanato Group S.p.A. with a buy rating and a price target of $25. Wolfe Research assumed coverage on June 2, 2026, also with a buy rating and a $21 target. The consensus among analysts is a buy recommendation, with a mean target price of $24.45 based on 10 analyst opinions.
About Stevanato Group S.p.A.
Stevanato Group S.p.A. is a healthcare company based in Piombino Dese, Italy. It designs and produces products for the biopharma and healthcare industries worldwide. The company operates in two segments: Biopharmaceutical and Diagnostic Solutions, and Engineering. Products include pre-fillable syringes, cartridges, and drug delivery systems. Founded in 1949, it employs over 6,000 people and is led by CEO Franco Stevanato.
Bottom Line
Elisabetta Magistretti's recent purchase of Stevanato Group shares reflects her confidence in the company's prospects. The stock's current valuation, along with recent analyst ratings, suggests ongoing interest in its performance. Investors should note that insider transactions like these are reported after the fact and are not necessarily indicative of future stock performance.
Get Stevanato Group S.p.A. alerts
New 13F filings, insider trades, and analyst moves on $STVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.